Monitor the company's leverage ratio and integration progress in the next quarterly report. The pending LaCorium acquisition (up to $95M additional debt) adds further leverage risk. Watch for any guidance updates on combined revenue and cost synergies.
Price Chart
Executive Summary
Prestige Consumer Healthcare completed its $1.045B acquisition of the Breathe Right brand from Foundation Consumer Brands, financed with a new Term Loan B and cash on hand. The deal adds the #1 nasal strip brand as the company's largest product, but comes on the heels of weak Q4 FY2026 earnings (revenue -5% YoY, EPS miss) and adds significant leverage to the balance sheet.
Key Financial Metrics
Key Facts
- Acquisition of Breathe Right and certain other brands closed on June 12, 2026 for $1.045B in cash
- Net cost approximately $900M after anticipated tax benefits of $150M
- Financed via a new $1.045B Term Loan B (Term SOFR + 2.00%) and available cash
- ABL credit facility amended: commitments increased to $225M, maturity extended to five years from closing
- Term Loan B permits an additional uncommitted draw of up to $95M for the pending LaCorium Health acquisition (expected Q2 FY2027)
- Breathe Right becomes Prestige's largest brand and represents expansion into the nasal strip category
- Quarterly amortization on Term Loan B is 0.25% of principal; mandatory prepayments triggered if first-lien net leverage exceeds 2.75x starting FY2028
Financial Impact
Total consideration $1.045B cash, net ~$900M after tax benefits; new debt of $1.045B added; ABL facility increased to $225M from prior level
Risk Factors
- High leverage from $1.045B term loan relative to $2.2B market cap and ~$1.09B annual revenue
- Integration risk for Breathe Right and potential disruption to existing brand portfolio
- Weak recent earnings (Q4 FY2026 revenue -5% YoY, EPS miss) raise concerns about cash flow coverage of debt service
- Pending LaCorium acquisition adds further debt and execution complexity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-074259 |
| Document: tm2618021d1_ex99-1.htm | 0001104659-26-074259 |
| Document: 0001104659-26-074259-index-headers.html | 0001104659-26-074259 |
| Document: 0001104659-26-074259-index.html | 0001104659-26-074259 |
| Document: 0001104659-26-074259.txt | 0001104659-26-074259 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $54.43 $52.56 | ▼ −3.44% | ▼ −4.04% | $45.26 (−16.85%) |
Jul 6, 2026 12w ago | Press Release | $48.86 $50.22 | ▲ +2.78% | ▲ +3.35% | $45.26 (−7.37%) |
Jun 16, 2026 15w ago | 8-K | $47.50 $47.19 | ▼ −0.65% | ▼ −0.85% | $45.26 (−4.72%) |
May 13, 2026 20w ago | 8-K | $45.93 $47.82 | ▼ −4.12% | ▼ −4.97% | $45.26 (+1.46%) |
May 7, 2026 21w ago | 144 | $54.59 $45.44 | ▼ −16.76% | ▼ −19.90% | $45.26 (−17.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access